Medical device manufacturers in the European Union are going to have to improve the quantity and quality of their postmarket clinical follow-up activities, a senior UK medical device regulator has warned. There is an increasing realisation that the necessary clinical data is not going to be obtained in the premarket setting
...
Please Login to read the full article.
